We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Sandoz Humira Biosimilar Set For 2023 After AbbVie Deal

Law360 (October 12, 2018, 6:58 PM EDT) -- Novartis AG unit Sandoz will get to launch its biosimilar of AbbVie Inc.’s immunosuppressant Humira in the U.S. on Sept. 30, 2023, and in Europe on Tuesday as part of a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.